Arcturus Therapeutics entered a strategic collaboration with Thermo Fisher to advance ARCT-032, its investigational mRNA therapy for cystic fibrosis. The Master Services Agreement provides up to $40 million in clinical manufacturing services from Thermo Fisher, alongside up to $40 million in CRO services via PPD. Thermo Fisher will gain exclusive commercial manufacturing rights upon approval of ARCT-032, to be detailed in a future supply agreement. A related Project Addendum with Patheon covers tech transfer, clinical supply manufacturing, fill-finish, release, and stability work to support development and potential commercialization.
Agreement 1: Arcturus Therapeutics, Thermo Fisher Strike ARCT-032 CRO/CDMO MSA: $40M Mfg + $40M CRO
- Agreement type: Master Services Agreement for CRO and CDMO collaboration on ARCT-032
- Counterparty: Thermo Fisher Scientific
- Signed / Effective: Jun 26 2026 / same
- Duration / Termination: 5 years, auto-renews annually
- Reason: Advance ARCT-032 development with integrated CRO and CDMO support
Agreement 2: Arcturus and Patheon Sign ARCT-032 Development Addendum Covering Tech Transfer and Clinical Supply
- Agreement type: Project Addendum for Development Services (manufacturing and related activities)
- Counterparty: Patheon UK
- Signed / Effective: Jun 26 2026 / same
- Duration / Termination: Until completion of services
- Reason: Prepare ARCT-032 for clinical and commercial readiness
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.